戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d endometrial cancers that do not respond to progestin therapy.
2  breast cancer risk from menopausal estrogen-progestin therapy.
3 ERS) was a randomized trial of estrogen plus progestin therapy after menopause.
4                                Estrogen plus progestin therapy among postmenopausal women with known
5 vestigate the relation between estrogen plus progestin therapy and risk of stroke among postmenopausa
6 udies now show that combination estrogen and progestin therapy appears to also result in a reduction
7                                 Estrogen and progestin therapy appears to have a more favorable effec
8 gnificant effect of 4 years of estrogen plus progestin therapy compared with placebo on knee pain and
9                   In addition, estrogen plus progestin therapy did not prevent mild cognitive impairm
10 HIMS) previously reported that estrogen plus progestin therapy does not protect cognition among women
11                  Postmenopausal estrogen and progestin therapy (EPT) increases mammographic percent d
12 strogen-alone therapy (ET) and estrogen plus progestin therapy (EPT), in perimenopausal or postmenopa
13                            MHT use (estrogen-progestin therapy [EPT] or estrogen-only therapy [ET]) i
14  prospective trial of combined estrogen plus progestin therapy for disease prevention.
15  with progestins may improve the efficacy of progestin therapy for the treatment of endometrial cance
16 benefit of estrogen therapy and estrogen and progestin therapy in observational studies of postmenopa
17 ls have examined the effect of estrogen plus progestin therapy in postmenopausal women on the risk fo
18           On July 8, 2002, the estrogen plus progestin therapy in the WHI trial was discontinued beca
19                                Estrogen plus progestin therapy increased the risk for probable dement
20                                Estrogen plus progestin therapy increased the risks associated with ag
21                                Estrogen plus progestin therapy increases the risk for coronary heart
22                                  Response to progestin therapy is more frequent among patients with a
23 gests that continuous combined estrogen plus progestin therapy may increase the risk of ovarian cance
24 clerosis and the extent to which concomitant progestin therapy may modify these effects.
25 r, about the effect of combined estrogen and progestin therapy on the risk of cardiovascular disease.
26 3.93, 95% CI: 1.43, 10.84), or estrogen-plus-progestin therapy (OR = 3.51, 95% CI: 1.45, 8.49).
27                 It showed that estrogen plus progestin therapy reduced fractures (46 fewer per 10 000
28  Conjugated estrogen, alone or combined with progestin therapy, reduced PAI-1 levels by approximately
29 itor activity, which was antagonized by anti-progestin therapy, strengthening this mechanistic link.
30                   In postmenopausal estrogen progestin therapy users, carriers of the less active AR-
31 eats predicts breast cancer risk in estrogen progestin therapy users.
32 rial cancers; however, the response rates to progestin therapy vary and the molecular mechanisms behi
33  individual and combined effects of estrogen/progestin therapy versus lovastatin on lipids and flow-m
34 rd ratio for continuous use of estrogen plus progestin therapy was 2.36 (95% CI, 1.55 to 3.62) for th
35                         Use of estrogen-plus-progestin therapy was not associated with the risk of pa
36 endometrioid tumors were found with estrogen/progestin therapy, whereas no association was found with
37 n's Health Initiative trial of estrogen-plus-progestin therapy, women assigned to active treatment ha